| ¿µ¹® | cervix cancer | ÇÑ±Û | Àڱøñ¾Ï, ÀڱðæºÎ¾Ï |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀÇ ¸ñÀº ÀÚ±ÃÀÌ Áú°ú ¿¬°áµÈ ºÎÀ§·Î ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ºÎÀ§ÀÌ´Ù. À̰÷ÀÇ »óÇǼ¼Æ÷¿¡¼ ¹ß»ýÇÏ´Â ¾ÏÀ» Àڱøñ¾ÏÀ̶ó°í ÇÑ´Ù. Àڱøñ¾ÏÀÇ ¹ß»ýÀ» »ìÆìº¸¸é ÀڱøñÀÇ »óÇǼ¼Æ÷°¡ ¿©·¯ °¡Áö Àڱؿ¡ ÀÇÇØ¼ Á¤»ó¼¼Æ÷¿Í Â÷À̳ª´Â ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ »ý±â°Ô µÈ´Ù. ÀÌ ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷´Â óÀ½¿¡´Â ÀڱøñÀÇ »óÇǼ¼Æ÷ÃþÀÇ ÀϺθ¦ ÀÌ·ç°í ÀÖ°Ô µÈ´Ù. ±×·¯´Ù°¡ Á¡Á¡ ´õ ÁøÇàÀÌ µÇ¸é ¾Ï¼º¼¼Æ÷°¡ Àڱøñ »óÇǼ¼Æ÷ÀÇ ¸ðµç ÃþÀ» ²Ëä¿ì°Ô µÈ´Ù. ±×¸®°í °è¼Ó ÁøÇàÇÏ¸é »óÇǼ¼Æ÷ÀÇ ¸Ç ¹Ø¿¡ ÀÖ´Â ¹Ù´Ú¸·À» ¶Õ°í ¹öÆÀÁ¶Á÷À¸·Î ħÀ±ÇØ µé¾î°¡°Ô µÈ´Ù. ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀÇ ÀϺθ¦ ä¿ì´Â °ÍÀ» ÀڱøñÇü¼ºÀÌ»ó(cervical dysplasia)¶ó°í ÇÏ°í ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀ» ¸ðµÎ ä¿ö¹ö·Á Á¤»óÀûÀÎ ¼¼Æ÷°¡ ¾ø´Â °æ¿ì¸¦ »óÇdz»¾ÏÁ¾(carcinoma in situ)¶ó°í ÇÑ´Ù. ±×¸®°í ¹Ù´Ú¸·À» ¶Õ°í ¹ØÀÇ ¹öÆÀÁ¶Á÷À¸·Î ħ¹üÇØ ³ª°¡´Â °æ¿ì¸¦ ħÀ±¾Ï(invasive cancer)¶ó°í ÇÑ´Ù. Àڱøñ¾ÏÀº ¿©·¯ ¸íÀÇ »ó´ë¿Í ¼º°ü°è¸¦ °¡Áö´Â ¿©ÀÚ, ±×¸®°í ù ¼º°æÇèÀÇ ³ªÀ̰¡ ¾î¸° ¿©ÀÚ¿¡°Ô¼ ÈçÇÏ°í ¶Ç »çȸÀû, °æÁ¦Àû ¼öÁØÀÌ ³·Àº »ç¶÷¿¡°Ô¼ Àß °É¸®´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ÀÌ·± °ÍÀ¸·Î ¹Ì·ç¾î Àڱøñ¼¼Æ÷ÀÇ ¾Ï¼ºº¯È¿¡´Â ¼ºº´°ú °°Àº °¨¿°ÀÌ Áß¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í, ¶Ç ¸î°¡Áö ¹ÙÀÌ·¯½ºÀÇ °¨¿°ÀÌ Àڱøñ¾ÏÀÇ ¿øÀÎÀ̶ó´Â °ÍÀÌ ¹àÇôÁ® ÀÖ´Ù. Àڱøñ¾ÏÀÇ Áø´Ü¹æ¹ýÀ¸·Î´Â Áú¼¼Æ÷°Ë»ç, ÄÝÆ÷½ºÄÚÇÇ, »ý°Ë(biopsy) µîÀÌ ÀÖ´Ù. ¼¼Æ÷°Ë»ç¶õ Á¶±âÁø´Ü ¸ñÀûÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ýÀ¸·Î ¼ØºÀÀ¸·Î ÀڱøñÀ»¸¦ ¹®Áú·¯¼ Àڱøñ»óÇǼ¼Æ÷¸¦ ¾ò°í À̰ÍÀ» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© »óÇǼ¼Æ÷ÀÇ º¯È¸¦ º¸´Â °ÍÀÌ´Ù. ÄÝÆ÷½ºÄÚÇǶõ ÀÚ±ÃÀÇ ¸ñÀ» 4~10¹è Á¤µµ È®´ëÇØ¼ º¸´Â ÀÏÁ¾ÀÇ È®´ë°æ°Ë»çÀ¸·Î Àڱøñ¾ÏÀ¸·Î ÀÎÇÑ ÀڱøñÀÇ º´Àûº¯È¸¦ °üÂûÇÏ¿© Áø´ÜÇÏ´Â °ÍÀÌ´Ù. »ý°Ë¶õ Áø´ÜÀ» À§Çؼ Á÷Á¢ ÀڱøñÀÇ Á¶Á÷À» ¶¼¾î äÃëÇÏ¿© Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Áø´ÜÇÏ´Â °ÍÀ¸·Î °¡Àå Á¤È®ÇÑ Áø´Ü¹ýÀÌ´Ù. Ä¡·á·Î´Â º´ÀÇ ÁøÇàÁ¤µµ¿¡ µû¶ó ´Ù¸£°ÚÁö¸¸ ¾ÏÀÇ ÁøÇàÀÌ °ÅÀÇ ¾ø¾î Çü¼ºÀÌ»óÀ̳ª Á¦ÀÚ¸®¾ÏÁ¾ ¶Ç´Â ¾ÆÁÖ Á¶±Ý ħÀ±ÇÏ¿´À» °æ¿ì¿¡´Â ¼ö¼úÀû¿ä¹ýÀ¸·Î ÀÚ±ÃÀ» ÀûÃâÇÏ´Â °ÍÀÌ Ä¡·áÀÇ ¿øÄ¢ÀÌ°í ¸¹Àº ÁøÇàÀ» º¸¿© ´Ù¸¥ Á¶Á÷À¸·Î ¾ÏÀÇ Ä§À±ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù. |
||
| ¿µ¹® | advanced cancer | ÇÑ±Û | ÁøÇà¾Ï |
|---|---|---|---|
| ¼³¸í | Á¶±â¾Ï¿¡ ´ëÇÑ ¸»·Î ¾ÏÀÇ °æ°ú°¡ ÁøÇàµÈ °ÍÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | lung cancer | ÇÑ±Û | Æó¾Ï |
|---|---|---|---|
| ¼³¸í | ÇãÆÄ¿¡ »ý±â´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. °¡Àå ¿¹Èİ¡ ³ª»Û Á¾¾çÁßÀÇ Çϳª·Î½á Á¶±â¹ß°ßÀÌ ¾î·Æ°í Áõ¼¼ ¶ÇÇÑ ´Ê°Ô ³ªÅ¸³ª¼, ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£³ª Ä¡·áÈÄ¿¡µµ ´ë°³ 8%¸¸ÀÌ 5³â »ýÁ¸ÀÌ °¡´ÉÇÑ ¾Ç¼ºÁ¾¾çÀÌ´Ù. À¯¹ßÀÎÀڷδ ´ëÇ¥ÀûÀ¸·Î ´ã¹è°¡ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, À¯ÀüÀûÀÎ ¿ä¼Òµµ ¾î´À Á¤µµ ±â¿©ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. |
||
| ¿µ¹® | cancer chemotherapy | ÇÑ±Û | Ç×¾ÏÈÇпä¹ý |
|---|---|---|---|
| ¼³¸í | ÈÇÐÀû ¹°ÁúÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. À̶§ »ç¿ëµÇ´Â ¹°ÁúÀ» Ç×¾ÏÁ¦¶ó°í ÇÑ´Ù. ÀÌ»óÀûÀÎ Ç×¾ÏÁ¦´Â Á¤»óÀûÀÎ ¼¼Æ÷¿¡´Â ÀÌ»óÀÌ ¾ø°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾î¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀÇ Æ¯ÀÌÇÑ Æ¯¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇÏ´Â ¾à¹°À» °³¹ßÇÏ¿©¾ß ÇÑ´Ù. ÃÖ±Ù ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº À¯ÀüÁ¤º¸¸¦ °¡Áö°í ÀÖ´Â DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â(DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡¼´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼µµ Á¤»óÀûÀ¸·Î Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒȰüÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ÀÌ·± ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î Ä¡¸íÀûÀÎ ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒȺҷ®ÀÌ À߿´Ù). |
||
| HSSCC | hereditary site-specific colon cancer |
|---|---|
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CC | calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card... |
| ICR | [distance between] iliac crests; Institute for Cancer Research; Institute for Cancer Research [mouse... |
| MBC | male breast cancer; maximal bladder capacity; maximal breathing capacity; metastatic breast cancer; ... |
| prostate-specific antigen | <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer. It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease. It is found in normal seminal fluid and produced by the prostatic epithelial cells. Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition. No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain. Acronym: PSA Registry number: EC 3.4.21.77 (22 Sep 2002) |
|---|---|
| nodular hyperplasia of prostate | Glandular and stromal hyperplasia occurring very commonly in the middle and lateral lobes of older men, forming nodules that may increasingly obstruct the urethra. Synonym: benign prostatic hypertrophy. (05 Mar 2000) |
| inferolateral surface of prostate | The surface of the prostate facing the body of the pubis and the pelvic diaphragm. Synonym: facies inferolateralis prostatae. (05 Mar 2000) |
| isthmus of prostate | The narrow middle part of the prostate anterior to the urethra. Synonym: isthmus prostatae. (05 Mar 2000) |
| elevator muscle of prostate | <anatomy> In the male, the most medial fibres of the levator ani (pubococcygeus) muscle that extend from the pubis into the fascia of the prostate. Synonym: musculus levator prostatae, elevator muscle of prostate. (05 Mar 2000) |
| fascia of prostate | The condensation of pelvic visceral fascia that encloses the prostate gland. Synonym: fascia prostatae. (05 Mar 2000) |
| female prostate | Term sometimes applied to the periurethral glands in the upper part of the urethra in the female. (05 Mar 2000) |
| lobe of prostate | One of the lateral lobes (right or left) or the middle lobe or isthmus of the prostate; in the adult the lobes are ill-defined. Synonym: lobus prostatae. (05 Mar 2000) |
| Albright's hereditary osteodystrophy | An inherited form of hyperparathyroidism associated with ectopic calcification and ossification and skeletal defects, notably the small fourth metacarpals, but intelligence is normal. There are dominant, recessive and X-linked forms. See: pseudohypoparathyroidism. Synonym: Albright's syndrome. (05 Mar 2000) |
| angioedema, hereditary | A genetic form of angioedema. (Angioedema is also referred to as Quinke's disease.) Persons with it are born lacking an inhibitor protein (called C1 esterase inhibitor) that normally prevents activation of a cascade of proteins leading to the swelling of angioedema. Patients can develop recurrent attacks of swollen tissues, pain in the abdomen, and swelling of the voice box (larynx) which can compromise breathing. The diagnosis is suspected with a history of recurrent angioedema. It is confirmed by finding abnormally low levels of C1 esterase inhibitor in the blood. Treatment options include antihistamines and male steroids (androgens) that can also prevent the recurrent attacks. Also called hereditary angioneurotic oedema. (12 Dec 1998) |
| angioneurotic oedema, hereditary | A genetic form of angioedema. (Angioedema is also referred to as Quinke's disease.) Persons with it are born lacking an inhibitor protein (called C1 esterase inhibitor) that normally prevents activation of a cascade of proteins leading to the swelling of angioedema. Patients can develop recurrent attacks of swollen tissues, pain in the abdomen, and swelling of the voice box (larynx) which can compromise breathing. The diagnosis is suspected with a history of recurrent angioedema. It is confirmed by finding abnormally low levels of C1 esterase inhibitor in the blood. Treatment options include antihistamines and male steroids (androgens) that can also prevent the recurrent attacks. Also called hereditary angioedema. (12 Dec 1998) |
| canine hereditary blindness | An autosomal dominant condition seen in dogs of the collie and several other breeds. (05 Mar 2000) |
| colourectal neoplasms, hereditary nonpolyposis | A syndrome characterised by autosomal dominant inheritance, a low mean age (41 years) for occurrence of colon cancer, and a marked increase in the proportion of tumours in the proximal colon. (12 Dec 1998) |
| corneal dystrophies, hereditary | Bilateral hereditary disorders of the cornea, usually autosomal dominant, which may be present at birth but more frequently develop during adolescence and progress slowly throughout life. Central macular dystrophy is transmitted as an autosomal recessive defect. (12 Dec 1998) |
| hereditary | <genetics> Transferred via genes from parent to child. (16 Dec 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|